At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
HS-110 (viagenpumatucel-L) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, First-in-human, Dose-escalation Study to Evaluate the Safety and Immunologic Response After Administration of HS-130 in Combination With HS-110 (Viagenpumatucel-L) in Patients With Solid Tumors Refractory to Standard Care
In Brief
A Phase 1 clinical trial evaluating HS-110 (viagenpumatucel-L) and HS-130 for Advanced Solid Tumor. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This is a phase 1 open-label, single center, dose escalation study to determine a safe and effective maximum tolerated dose of HS-130 in combination with viagenpumatucel-L (HS-110) for adult subjects with advanced solid tumors who are refractory to Standard of Care.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartOct 2019
Primary CompletionAug 2021
Study CompletionApr 2022
TodayJul 2026
First PostedOct 7, 2019
Enrollment StartOct 18, 2019
Primary CompletionAug 12, 2021
Study CompletionApr 1, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.7 years ago
Interventions
HS-110 (viagenpumatucel-L)biological
Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
HS-130biological
Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig